Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Letters to the Editor

Brentuximab vedotin plus nivolumab as bridging therapy to CAR T-cells in relapsed/refractory primary mediastinal B-cell lymphoma

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy; IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy; IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
IRCCS Humanitas Research Hospital, Department of Oncology and Hematology, Rozzano (MI)
Haematologica Early view Sep 18, 2025 https://doi.org/10.3324/haematol.2025.287672

Abstract

Not available.

Figures & Tables

Article Information

Early view : Letters to the Editor
 
DOI
https://doi.org/10.3324/haematol.2025.287672
Pubmed
40963380
 
Published
2025-09-18
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2025 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views
636
PDF Downloads
261

Statistics from Altmetric.com

No Data
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2025 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online